university website

E.G. Kamburova, B.W. Wisse, I. Joosten (Irma), W.A. Allebes (Wil), A. van der Meer, L.B. Hilbrands (Luuk), M.C. Baas (Marije), E. Spierings (E.), C.E. Hack (Erik), F. van Reekum, et al. Van Zuilen, A.D. (Arjan D.), M.C. Verhaar (Marianne), M.L. Bots (Michiel), A.C.A.D. Drop, L. Plaisier, M.A.J. Seelen, J.S.F. Sanders, B.G. Hepkema (Bouke), A.J.A. Lambeck (Annechien J.A.), L.B. Bungener, C. Roozendaal, M.G.J. Tilanus (Marcel), C.E.M. Voorter (C. E M), L. Wieten, E. van Duijnhoven, M. Gelens, M.H. Christiaans (Maarten), F. van Ittersum, S.A. Nurmohamed (Shaikh Azam), N.M. Lardy (Neubury), W.T. Swelsen, K.A. van der Pant, N.C. van der Weerd (Neelke), I.J.M. ten Berge (Ineke), F.J. Bemelman (Fréderike), A.J. Hoitsma (Andries), P.J.M. van der Boog, J.W. de Fijter (Johan), M.G.H. Betjes (Michiel), P.J. Heidt (Peter), D.L. Roelen (Dave), F.H.J. Claas (Frans) and H.G. Otten (Henderikus)

2018-09-01

Pretransplant C3D-fixing donor-specific anti-HLA antibodies are not associated with increased risk for kidney graft failure

Publication

Publication

American Society of Nephrology. Journal , Volume 29 - Issue 9 p. 2279- 2285

Background Complement-fixing antibodies against donor HLA are considered a contraindication for kidney transplant. A modification of the IgG single-antigen bead (SAB) assay allows detection of anti-HLA antibodies that bind C3d. Because early humoral graft rejection is considered to be complement mediated, this SAB-based technique may provide a valuable tool in the pretransplant risk stratification of kidney transplant recipients. Methods Previously, we established that pretransplant donor-specific anti-HLA antibodies (DSAs) are associated with increased risk for long-term graft failure in complement-dependent cytotoxicity crossmatch-negative transplants. In this study, we further characterized the DSA-positive serum samples using the C3d SAB assay. Results Among 567 pretransplant DSA-positive serum samples, 97 (17%) contained at least one C3d-fixing DSA, whereas 470 (83%) had non-C3d-fixing DSA. At 10 years after transplant, patients with C3d-fixing antibodies had a death-censored, covariate-adjusted graft survival of 60%, whereas patients with non-C3d-fixing DSA had a graft survival of 64% (hazard ratio, 1.02; 95% confidence interval, 0.70 to 1.48 for C3d-fixing DSA compared with non-C3d-fixing DSA; P50.93). Patients without DSA had a 10-year graft survival of 78%. Conclusions The C3d-fixing ability of pretransplant DSA is not associated with increased risk for graft failure.

Additional Metadata
Persistent URL doi.org/10.1681/ASN.2018020205, hdl.handle.net/1765/110071
Journal American Society of Nephrology. Journal
Organisation Department of Internal Medicine
Citation
Kamburova, E. G., Wisse, B. W., Joosten, I., Allebes, W., van der Meer, A., Hilbrands, L., … Otten, H. (2018). Pretransplant C3D-fixing donor-specific anti-HLA antibodies are not associated with increased risk for kidney graft failure. American Society of Nephrology. Journal, 29(9), 2279–2285. doi:10.1681/ASN.2018020205


User Publication Person Organisation Collection
Close